agilon health, inc. — fact timeline

agilon health, inc. shareholders approved Non-binding vote on executive compensation at the 2026-06-02 meeting.

“The stockholders approved, on an advisory, non-binding basis, the compensation paid to the Company’s named executive officers.”

agilon health, inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.

“The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

agilon health, inc. shareholders approved Election of three Class II directors at the 2026-06-02 meeting.

“The following three individuals were elected to the Company's Board of Directors to serve as Class II directors until the Company's 2029 annual meeting of stockholders and until their successors have been duly elected and qualified.”

agilon health, inc. reported the first quarter ended March 31, 2026 results: revenue $1.42 billion, net income $49 million. Guidance raised.

“previously disclosed market exits, as well as payor exits in certain markets resulting from a disciplined approach to contracting focused on profitability. • Total revenue of $1.42 billion in the first quarter 2026 decreased 7% compared to $1.53 billion in the first quarter 2025. Revenue reflects lower year-over-year membership partially offset by improved pricing,”

agilon health, inc.: Filed Certificate of Amendment to effect a 1-for-25 reverse stock split of common stock (effective 2026-03-30).

“On March 30, 2026, agilon health, inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.01 per share (the “Common Stock”).”

agilon health, inc. incurred guarantee.

“Substantially concurrently with the effectiveness of the Amendment, the Company executed and delivered an unsecured guaranty of Management’s obligations under the Credit Agreement (the “Parent Guaranty”).”

agilon health, inc. amended credit facility of $90.0 million with J.P. Morgan Chase Bank, N.A., as administrative agent maturing February 18, 2028.

“the Amendment, among other changes, (a) extended the stated maturity date from February 18, 2026 to February 18, 2028; (b) amended certain covenant “baskets” to be measured as a percentage of EBITDA rather than, or as an alternative to, Consolidated Total Assets; (c) required that Management maintain a minimum of $50 million in Total Cash as of the end of each Business Day; (d) conditioned certain payments, including dividends, to Holdings under the available amount “basket” on the Company achieving positive EBITDA for two consecutive trailing four-quarter periods each ending after the Third Amendment Effective Date; (e) required that any reduction in outstanding letters of credit be accompanied by a corresponding prepayment of term loans; (f) reduced the aggregate amount of revolving credit commitments from $100.0 million to $90.0 million; and (g) required cash collateralization at 103% of the amount of each letter of credit outstanding immediately prior to the Third Amendment Effecti”

agilon health, inc. amended Third Amendment to the Credit Agreement with J.P. Morgan Chase Bank, N.A., as administrative agent, and the other lenders and issuers party thereto (effective 2026-02-12).

“On February 12, 2026 (the “Third Amendment Effective Date”), agilon health, inc. (the "Company"), agilon health management, inc. (f/k/a agilon health, inc.) (the “Management”) and Agilon Health Intermediate Holdings, Inc. (“Holdings”), entered into the Third Amendment (the “Amendment”) to the Credit Agreement”

agilon health, inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“November 5, 2025, agilon health, inc. (the “Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) informing the Company that it is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period ended November 4, 2025 (the “Price Criteria for Capital or Common Stock”). The Company can regain compliance at any time within the six-month period following receipt of the Notice if, on the last trading day of an”

agilon health, inc.: Amended and restated the bylaws to adopt amendments relating to officer positions and technical updates reflecting Delaware law changes (effective 2025-07-29).

“On July 29, 2025, the Board amended and restated the by-laws of the Company (as amended, the “Amended and Restated By-laws”).”

Jeff Schwaneke resigned as Director at agilon health, inc..

“In connection with his appointment, Mr. Schwaneke will resign from the agilon health, inc. Board of Directors.”

Jeff Schwaneke was appointed as Chief Financial Officer and Executive Vice President at agilon health, inc..

“On June 4, 2024, agilon health, inc. (the “Company”) appointed Jeff Schwaneke to serve as the Company’s Chief Financial Officer and Executive Vice President effective July 1, 2024 (the “Effective Date”).”

agilon health, inc. updated its the first quarter ended March 31, 2024 guidance (reaffirmed).

“On May 7, 2024 , agilon health, inc. (the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three months ended March 31, 2024.”

agilon health, inc. reported the three and twelve months ended December 31, 2023 results: revenue Total revenue of $1.06 billion in the fourth quarter 2023 increased 72% compared to $615 million in the fourth quarter 2, net income Net loss of $230 million in the fourth quarter 2023 compared to a loss of $57 million in the fourth quarter 2022. For th. Guidance reaffirmed.

“On February 27, 2024 , agilon health, inc. (“agilon” or the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three and twelve months ended December 31, 2023.”

Karthik Rao was appointed as Interim Chief Medical Officer at agilon health, inc..

“Until a successor is named, Dr. Karthik Rao, senior medical director and vice president, network performance, will serve as interim CMO.”

Benjamin Kornitzer, M.D. changed role as Chief Medical Officer at agilon health, inc..

“Effective March 1, 2024, Benjamin Kornitzer, M.D., will assume a strategic role as special advisor to agilon health and will transition from his role as chief medical officer (CMO).”